Citizen Petition from Covington & Burling LLP on Behalf of Novo Nordisk Inc.

An individual patient expresses strong opposition to the proposed action, arguing that it would restrict access to affordable compounded GLP-1 medications. They state that these medications are life-changing and necessary for patients who face significant cost barriers or lack insurance coverage.

The commenter opposes the proposed action, arguing that it is designed to protect the profits of large corporations rather than public health. They claim the measure will restrict access to cheaper, out-of-pocket compounding medications in favor of more expensive "name brand" services controlled by insurance companies.